Vor Biopharma Inc.
About Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$696.0M
- Total assets
- $464.1M
- Market cap
- $713.1M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $371.6M
- Operating income
- -$371.6M
- Net income
- -$696.0M
- EPS (basic)
- $-70.50
- EPS (diluted)
- $-70.50
Balance sheet
- Total assets
- $464.1M
- Current assets
- $458.1M
- Total liabilities
- $628.4M
- Current liabilities
- $25.2M
- Shareholders’ equity
- -$164.3M
Cash flow
- Operating cash flow
- -$142.7M
- Investing cash flow
- -$48.8M
- Financing cash flow
- $503.8M
- Net cash flow
- $312.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $713.1M
- EPS (diluted)
- $-70.5
- Shares outstanding
- 53.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 5, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $696.0M.
- Trading 75% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Vor Biopharma Inc..
Write a review
News about Vor Biopharma Inc.
News & sentiment via Polygon.io
